Transcode Therapeutics Inc Asset Resilience Ratio
Transcode Therapeutics Inc asset resilience ratio. Transcode Therapeutics Inc (RNAZ) has an Asset Resilience Ratio of 0.17% as of March 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See RNAZ days of operational coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Transcode Therapeutics Inc (2020–2022)
Asset resilience ratio of Transcode Therapeutics Inc from 2020 to 2022. This chart shows how Transcode Therapeutics Inc's Asset Resilience Ratio has changed over time. Read Transcode Therapeutics Inc (RNAZ) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Transcode Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of Transcode Therapeutics Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $9.41K | 0.17% |
| Total Liquid Assets | $9.41K | 0.17% |
Asset Resilience Insights
- Limited Liquidity: Transcode Therapeutics Inc maintains only 0.17% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Transcode Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Transcode Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Transcode Therapeutics Inc Asset Resilience Ratio by Year (2020–2022)
Transcode Therapeutics Inc asset resilience ratio by year from 2020 to 2022. The table below shows the annual Asset Resilience Ratio data for Transcode Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-12-31 | 0.12% | $9.41K | $7.59 Million | +0.12pp |
| 2021-12-31 | 0.00% | $9.41 | $22.94 Million | 0.00pp |
| 2020-12-31 | 0.00% | $3.20 | $1.06 Million | -- |
About Transcode Therapeutics Inc
TransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. The company's therapeutic candidate comprises SEVIPROTIMUT-L for the adjuvant treatment of patients with Stages IIB and IIC melanoma that has completed Phase 2 clinical trial; TTX-MC138 that targets microRNA-10b, a master regulator of metastati… Read more